Sarbajit Mukherjee, Chief of GI Medical Oncology at Miami Cancer Institute and Co-Chair of GI Clinical Trial Working Group at Hoosier Cancer Research Network, shared a post on LinkedIn:
“Really enjoyed being part of Spectrum Conference Miami 2026 to speak on conversion therapy in liver-metastatic colorectal cancer—thank you Dr.Narayanan for the invitation!
Beyond the talk, participating in the multidisciplinary tumor board was a highlight. At Miami Cancer Institute, this kind of team-based discussion is how we care for patients everyday.
A few key takeaways:
- Early molecular profiling should guide strategy
- Tumor biology matters as much as anatomy
- Resectability is dynamic, not a one-time call
- Early and repeated multidisciplinary discussion changes outcomes
Conversion therapy works best when it’s treated as an evolving process and a true team effort.”
More posts from Sarbajit Mukherjee on OncoDaily.